Back to search

Peptide record

TPDB03611

Antibacterial Anticancer Antifungal Toxicity standard
10 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB03611
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia dbACP CAFPdb dbAMP
standard
No
A 10-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, dbACP, and other sources, with an available 3D structural model.
Sequence
KKLKKFKKLQ
Physicochemical Analysis
C62H113N17O12
ARNDCEGHIMPSTWYV
K
1288.69
11.21
6
0
3
+6
4.27
-1.650
78.00
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
1
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
1
Q
0
G
0
H
0
I
2
L
6
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 1 G: 0 H: 0 I: 0 L: 2 K: 6 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
10
C62H113N17O12
1288.69
11.21
+6
4.27
-1.650
Evidence Records 5 records
Evidence 1 Activity

Activity

17% Hemolysis
Toxicity
375 µM
Hemolytic Cytotoxic
17% Hemolysis | 375 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evidence 2 Activity

Activity

IC50
Toxicity
56.5±0.7 µM
Cytotoxic
IC50 | 56.5±0.7 | µM | target cell: Non-malignant human fibroblasts N1

Target

Non-malignant human fibroblasts N1

Source & Reference

NA
DBAASP
Antimicrobial cyclic decapeptides with anticancer activity | Peptides | 2010
Evidence 3 Activity

Activity

3% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
3% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A convenient solid-phase strategy for the synthesis of antimicrobial cyclic lipopeptides. | Org Biomol Chem | 2013
Evidence 4 Activity

Activity

4% Hemolysis
Toxicity
150 µM
Hemolytic Cytotoxic
4% Hemolysis | 150 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A convenient solid-phase strategy for the synthesis of antimicrobial cyclic lipopeptides. | Org Biomol Chem | 2013
Evidence 5 Activity

Activity

IC50
Toxicity
17
Hemolytic
Hemolytic_activity: Human erythrocytes: 17 ± 1.7% Hemolysis=375 µM IC50=17 ± 1.7 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Peptides. 2010 Nov 31(11):2017-26